Global Ligase Market Grows Steadily at a CAGR of 5%

Introduction

Ligases are specialized enzymes that facilitate the joining of two giant molecules, such as deoxyribonucleic acid (DNA). In addition to being widely utilized in next-generation sequencing, mutation detection, cloning, and gene synthesis, these enzymes are also used to cure genetic dysfunctions. Moreover, ligases are exploited in therapeutic applications in isolated and conjugated forms with various medications or therapy. They are also referred to as therapeutic enzymes. These enzymes treat cancer, cardiovascular ailments, and hereditary diseases. Many ligases exist, including T4DNA ligase, RNA ligase, and ubiquitin ligase. These enzymes regulate proteins' function and stability, generating inhibitors for preventing specific diseases.

Market Dynamics

Rising Incidence of Diseases and Genetic Disorders Drive the Global Ligase Market

The rising frequency of chronic diseases such as cancer among humans stimulates interest in and demand for novel treatment methods that provide superior patient care. Cancer propensity is characterized by DNA repair abnormalities in inherited human diseases, including inherited forms of colon and breast cancer. In the case of hereditary breast cancers, the development of Poly (ADP-ribose) polymerase inhibitors serves as therapies that specifically target DNA repair deficiency. These inhibitors of other DNA repair proteins may have anticancer applications. The increasing prevalence of genetic abnormalities and infectious diseases has prompted researchers and diagnosticians to use ligase enzymes to investigate and treat various pathogens. Abnormalities distinguish these genetic and viral diseases in the bone marrow, malignancy, radiosensitivity, and genomic instability. While no lagging strands would be consolidated without DNA ligase activity, leading strand fusion would be primarily impaired.

Utilization of PCR-Based Frameworks Creates Tremendous Opportunities

In diagnostic research, the novel application of this biochemical technology has a wide range of potential applications. This includes pathogen identification, testing for infectious diseases, and human genetic testing. The prevalence of chronic infections and disorders caused by microorganisms such as bacteria, viruses, fungi, and parasites has accelerated the development of the qPCR and dPCR frameworks. As a result, the need for ligase enzymes has increased. In response to this market demand, notable manufacturers have introduced cutting-edge ligases to develop qPCR and dPCR kits. The need for high-quality ligase enzymes is anticipated to increase in the upcoming years. This market trend would positively influence the global ligase market's growth.

Regional Analysis

North America is the highest revenue contributor and is estimated to exhibit a CAGR of 5.1% during the forecast period. In the ligase market category, North America is the dominant regional subdivision. This location is also the hub of numerous biotechnology companies and the epicenter of technical progress. Due to a growth in research and development (R&D) to develop ligases as therapeutic agents for cancer and other disorders, North America is anticipated to lead the market during the projection period. Due to the use of ligases in protein engineering, polymerase chain reaction, mutation detection, cloning, drug targeting, and next-generation sequencing, the worldwide ligase market is experiencing significant growth. In the upcoming years, they are projected to provide growth prospects because of the rise of genetic illnesses. Due to its enormous contribution to the ligase market, North America is anticipated to generate substantial income. It is also expected to dominate the market during the projection period.

Europe is anticipated to grow at a CAGR of 5.6% during the forecast period. The biotechnology and molecular enzymes industry is dominant in Europe, and biochemical breakthroughs have accelerated the modernization of the European life sciences sector. Throughout quite some time, Europe has utilized ligase enzymes in chemical analysis and as a research tool in the life sciences. European Molecular Biology Laboratory (EMBL) researchers completed several research and innovation initiatives that are one of the reasons driving the regional market.

Key Highlights

• The global ligase market was worth USD 390.21 million in 2022 and is estimated to reach an expected value of USD 620.71 million by 2031, growing at a CAGR of 5% during the forecast period (2023 – 2031).
• By product, the global ligase market is segmented into Quick Ligase, T4 DNA Ligase, E.coli DNA Ligase, Tth DNA Ligase, T4 RNA Ligase, Pfu DNA Ligase, and others. The T4 DNA Ligase segment dominates the market and is estimated to exhibit a CAGR of 6.4% during the forecast period.
• By source, the global ligase market is segmented into archaebacterium, thermus thermophilus, pyrococcus furiosus, escherichia coli, and others. The Escherichia coli segment dominates the market and is estimated to exhibit a CAGR of 6% during the forecast period.
• By application, the global ligase market is segmented into molecular cloning, next-generation sequencing, ligase, chain reaction, ligase detection reaction, repeat expansion detection, rolling circle amplification, proximity ligation assay, ligation-mediated PCR, mutation detection, and others. The molecular cloning segment dominates the market and is estimated to exhibit a CAGR of 6% during the forecast period.
• By end-user, the global ligase market is segmented into academic and research institutes, pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, and others. The academic and research institutes segment dominates the market and is estimated to exhibit a CAGR of 6.1% during the forecast period.
• North America is the highest revenue contributor and is estimated to exhibit a CAGR of 5.1% during the forecast period.

Competitive Players

1. Agilent Technologies Inc
2. ArcticZymes Technologies ASA
3. Bio-Rad Laboratories Inc
4. Codexis Inc
5. Hoffmann-La Roche Ltd
6. Inspiralis Limited Inc
7. Merck KGaA
8. New England Biolabs (UK) Ltd.
9. Promega Corporation
10. QIAGEN N.V
11. SBS Genetech
12. Takara Bio Inc
13. Thermo Fisher Scientific Inc
14. Tinzyme Ltd.
15. Vividion Therapeutics.

Recent Developments

Recent Development

• February 2023 - Leaders from Agilent Technologies Inc. joined Colorado Governor Jared Polis and local government officials to break ground on Agilent's USD 725 million investment to the double manufacturing capacity therapeutic nucleic acids in Frederick, Colorado.
• February 2023 - Agilent Technologies Inc. announced the release of new NovoExpress software that introduces integrated compliance tools for NovoCyte flow cytometer systems. The compliance-enabling features enable users to meet regulatory requirements defined in FDA 21 CFR Part 11 and Annex 11.

Segmentation

1. By Product
   1. Quick Ligase 
   2. T4 DNA Ligase 
   3. E. coli DNA Ligase 
   4. Tth DNA Ligase 
   5. T4 RNA Ligase 
   6. Pfu DNA Ligase 
   7. Others
2. By Source
   1. Archaebacterium 
   2. Escherichia coli 
   3. Thermus thermophilus 
   4. Pyrococcus furiosus 
   5. Others 
3. By Applications
   1. Ligase Chain Reaction (LCR)
   2. Ligase Detection Reaction (LDR)
   3. Next-Generation Sequencing (NGS) 
   4. Repeat Expansion Detection (RED) 
   5. Rolling Circle Amplification (RCA)
   6. Proximity Ligation Assay (PLA) 
   7. Molecular Cloning 
   8. Ligation Mediated PCR 
   9. Mutation Detection 
   10. Others 
4. By End-User
   1. Research Laboratories and Institutions 
   2. Pharmaceutical and Biopharmaceutical Companies 
   3. Diagnostic Laboratories 
   4. Others